345 related articles for article (PubMed ID: 32814993)
21. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
[TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
23. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Mathews SE; Kumar RB; Shukla AP
Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):315-320. PubMed ID: 30074500
[TBL] [Abstract][Full Text] [Related]
24. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
25. Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin.
Gawrieh S; Harlow KE; Pike F; Yates KP; Wilson LA; Cummings OW; Rosenberg WM; Chalasani N; Molleston JP
J Pediatr; 2021 Dec; 239():161-167.e5. PubMed ID: 34400208
[TBL] [Abstract][Full Text] [Related]
26. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
Ji HF; Sun Y; Shen L
Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
[TBL] [Abstract][Full Text] [Related]
27. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Ahmed A; Wong RJ; Harrison SA
Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
[TBL] [Abstract][Full Text] [Related]
28. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
29. Fatty liver disease and obesity in youth.
Della Corte C; Mazzotta AR; Nobili V
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):66-71. PubMed ID: 26702852
[TBL] [Abstract][Full Text] [Related]
30. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
Agrawal S; Duseja A
Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
[TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
[TBL] [Abstract][Full Text] [Related]
33. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
34. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
[TBL] [Abstract][Full Text] [Related]
35. Nonalcoholic Fatty Liver Disease and Obesity Treatment.
Brunner KT; Henneberg CJ; Wilechansky RM; Long MT
Curr Obes Rep; 2019 Sep; 8(3):220-228. PubMed ID: 30945129
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Kogachi S; Noureddin M
Clin Ther; 2021 Mar; 43(3):455-472. PubMed ID: 33581876
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
[TBL] [Abstract][Full Text] [Related]
38. Nonalcoholic Liver Disease in Children and Adolescents.
Smith SK; Perito ER
Clin Liver Dis; 2018 Nov; 22(4):723-733. PubMed ID: 30266159
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients.
Cheung A; Figueredo C; Rinella ME
Am J Gastroenterol; 2019 Apr; 114(4):579-590. PubMed ID: 30839326
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease.
Vittorio J; Lavine JE
F1000Res; 2020; 9():. PubMed ID: 32509277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
